News · 26 weeks35-92%
2025-12-142026-06-07
Mix1790d
- Insider8(47%)
- SEC Filings5(29%)
- Other3(18%)
- Market1(6%)
Latest news
25 items- SECSEC Form 6-K filed by Immuron Limited6-K - Immuron Ltd (0001660046) (Filer)
- INSIDERNew insider Palumbo Flavio claimed ownership of 1,142,909 units of Ordinary Shares (SEC Form 3)3 - Immuron Ltd (0001660046) (Issuer)
- INSIDERNew insider Pollock Daniel Jude claimed ownership of 743,230 units of Ordinary Shares (SEC Form 3)3 - Immuron Ltd (0001660046) (Issuer)
- SECSEC Form 6-K filed by Immuron Limited6-K - Immuron Ltd (0001660046) (Filer)
- PRPresenting on Emerging Growth Conference 92 Day 2 on May 7; Register to live streamMIAMI, May 06, 2026 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 92nd Emerging Growth Conference on May 6 & 7, 2026. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: Questions@EmergingGrowth.com For updates, follow us on Twitter. Presenting today – Wednesday, May 6, 2026 9:00Virtual Lobby opens.Register for the Conference. If you already registered, go
- PRPresenting on Emerging Growth Conference 92 Day 1 on May 6; Register to live streamMIAMI, May 05, 2026 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 91st Emerging Growth Conference on May 6 & 7, 2026. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: Questions@EmergingGrowth.com For updates, follow us on Twitter Day 1 - WednesdayMay 6, 2026 9:00Virtual Lobby opens.Register for the Conference. If you already registered, go back to the re
- INSIDERSEC Form 3 filed by new insider Brennan Paul Gerard3 - Immuron Ltd (0001660046) (Issuer)
- SECSEC Form 6-K filed by Immuron Limited6-K - Immuron Ltd (0001660046) (Filer)
- INSIDERNew insider Kanellos Jerry claimed ownership of 333,000 units of Ordinary Shares (SEC Form 3)3 - Immuron Ltd (0001660046) (Issuer)
- INSIDERNew insider Lydeamore Steven George claimed ownership of 3,155,047 units of Ordinary Shares (SEC Form 3)3 - Immuron Ltd (0001660046) (Issuer)
- INSIDERSEC Form 3 filed by new insider Joughin Jeannette Anne3 - Immuron Ltd (0001660046) (Issuer)
- INSIDERSEC Form 3 filed by new insider Laurita Aaron James3 - Immuron Ltd (0001660046) (Issuer)
- INSIDERNew insider Savarirayan Ravi claimed ownership of 877,840 units of Ordinary Shares (SEC Form 3)3 - Immuron Ltd (0001660046) (Issuer)
- NEWSEmerging Growth Research Releases Flash Report on Immuron; Maintains Buy-Extended Rating and Raises Price Target to $4.00NEW YORK CITY, NY / ACCESS Newswire / April 22, 2026 / Emerging Growth Research today released a Flash Report on Immuron (NASDAQ:IMRN), maintaining its Buy-Extended rating while increasing its 12-month price target to $4.00 (from $3.90), representing significant upside from the current share price of $0.9268 as of April 21, 2026.The Flash Report highlights Immuron's continued revenue growth, expanding commercial footprint, and progress within its clinical development pipeline.Key Highlights:Double-Digit Revenue Growth: Immuron reported global product revenue of AUD $1.5 million for 3Q FY2026, representing a 16% year-over-year increase. Growth was primarily driven by increased sales of Travel
- SECSEC Form 6-K filed by Immuron Limited6-K - Immuron Ltd (0001660046) (Filer)
- PRImmuron Double Digit 3Q Sales GrowthSales Highlights (unaudited): Global Q3 sales AUD$1.5 million up 16% on prior comparative period (pcp)YTD Mar 2026 sales AUD$5.7 million up 7% on prior comparative period (pcp) Australia Q3 sales AUD$0.9 million up 15% on prior comparative period (pcp)YTD Mar 2026 sales AUD$4.2 million up 14% on prior comparative period (pcp) Canada Q3 sales AUD$0.1 million up >100% on prior comparative period (pcp)Q3 sales up 82% on prior quarter; initial sales to Jean Coutu, QuebecYTD Mar 2026 sales AUD$0.1 million down 65% on prior comparative period (pcp) USA Q3 sales AUD$0.5 million up 1% on prior comparative period (pcp)YTD Mar 2026 sales AUD$1.3 million up 10% on prior comparative period (pcp)
- SECSEC Form 6-K filed by Immuron Limited6-K - Immuron Ltd (0001660046) (Filer)
- NEWSEmerging Growth Research Issues Flash Update on Immuron Limited, Maintains Buy-Extended Rating and $3.90 Price TargetNEW YORK CITY, NEW YORK / ACCESS Newswire / March 5, 2026 / Emerging Growth Research today released a Flash Research Update on Immuron Limited (NASDAQ:IMRN), maintaining its Buy-Extended rating and 12-month price target of $3.90 following the Company's release of first-half fiscal year 2026 financial results and strategic update.The Flash Report notes that Immuron reported global product revenue of AUD $4.18 million for the six months ended December 31, 2025, representing approximately 5% growth compared to the prior-year period. Revenue performance was supported by continued demand in Australia and the United States.By geography, Australian revenue increased 13% year-over-year, while U.S. r
- SECSEC Form 6-K filed by Immuron Limited6-K - Immuron Ltd (0001660046) (Filer)
- PRImmuron CEO, Steven Lydeamore presentation at Coffee Microcaps ConferenceMELBOURNE, Australia, March 05, 2026 (GLOBE NEWSWIRE) -- Immuron Limited ((ASX: IMC, NASDAQ:IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to advise our Chief Executive Officer, Steven Lydeamore is presenting virtually at the Coffee Microcaps Conference on Thursday 5th March 2026 (11:00am – 11:30am Australian Eastern Time). A copy of the presentation slide deck is available on the Company's website: https://investors.immuron.com.au/announcements/7418301 COMPANY CONTACT: Steven LydeamoreChief Executive Officersteve@immuron.com About ImmuronImmuron Limited ((ASX: IMC, NASDAQ:IMRN), is an Australian biopharmaceutical company focused on developing
- SECSEC Form 6-K filed by Immuron Limited6-K - Immuron Ltd (0001660046) (Filer)
- PRImmuron Reports HY26 Results and Strategic ResetHighlights (unaudited): Consistent Revenue Growth: Immuron is no longer just a "concept" company. Global H1 FY26 sales grew to AUD$4.2 million, with the U.S. market showing strong momentum (+17% YoY).Cash (AUD $10.0 million) to fund operating activities. Includes AUD $7.3 million (net) raised at an average price of A$0.0803 (IMRN USD$2.0923).Validated Platform: The "Hyper-Immune" platform is versatile. Beyond traveler's diarrhea (Travelan®), the company is moving into high-value clinical targets like C. diff (IMM-529)Partnerships: Immuron has taken a strategic decision to pursue partnerships to fund progress of Travelan® (IMM-124E) and IMM-529 clinical programs. IMM-124E: Eligible for end o
- SECSEC Form 6-K filed by Immuron Limited6-K - Immuron Ltd (0001660046) (Filer)
- SECSEC Form 6-K filed by Immuron Limited6-K - Immuron Ltd (0001660046) (Filer)
- SECSEC Form 6-K filed by Immuron Limited6-K - Immuron Ltd (0001660046) (Filer)
IMRN FAQ
6 questionsWhat does Immuron Limited do?
Immuron Limited, a biopharmaceutical company, researches and develops oral immunotherapy polyclonal antibodies for the treatment and prevention of infectious and immune modulated diseases in Australia, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. The company markets Travelan and Protectyn for the prevention of travellers' diarrhea. Its lead product candidates include IMM-124E that is in Phase II clinical trials for non-alcoholic steatohepatitis, severe alcoholic hepatitis, and non-alcoholic fatty liver...Where does IMRN stock trade?
Immuron Limited (IMRN) is listed on NASDAQ.What sector and industry is IMRN in?
Immuron Limited operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Immuron Limited go public?
Immuron Limited (IMRN) completed its IPO in 2017.What companies are similar to IMRN?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare IMRN side-by-side with any of them on Quantisnow.How can I track IMRN on Quantisnow?
Quantisnow aggregates Immuron Limited's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow IMRN to receive live email and push alerts on every new disclosure.